Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications

@article{Herring2019OrexinRA,
  title={Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications},
  author={W. Joseph Herring and Thomas Roth and Andrew D. Krystal and David Michelson},
  journal={Journal of Sleep Research},
  year={2019},
  volume={28}
}
In this review, we outline the role of orexin receptor antagonists in disorders of sleep/wake and other potential neuropsychiatric conditions, with a focus on suvorexant, which is currently the only approved agent in this class. The efficacy of suvorexant was established in Phase 2–3 trials with treatment durations ranging from 1 to 12 months in patients with insomnia. Suvorexant is effective at improving sleep assessed by patient self‐report and by polysomnography, with generally little effect… 

Daridorexant for the Treatment of Insomnia.

TLDR
Daridorexant is a dual orexin type 1 and types 2 (OX1 and OX2) receptor antagonist that was recently approved by the US FDA for the treatment of adults suffering from insomnia and was shown to be effective in reducing insomnia symptoms, increasing daytime functioning, and improving the overall quality of sleep.

Effect of ramelteon coadministered with antidepressant in patients with insomnia and major depressive disorder: an exploratory study

TLDR
Results from this exploratory study suggest that ramelteon may be effective and well tolerated in the treatment of sleep-onset insomnia in patients with concurrent depression.

Hypocretins (orexins): The ultimate translational neuropeptides

TLDR
Circuit neuroscience findings suggest that the Hcrt system is a hub that integrates diverse inputs modulating arousal and conveys this information to multiple output regions and highlights the potential of the HCrt system as a therapeutic target for a number of disorders.

Involvement of orexinergic system in psychiatric and neurodegenerative disorders: A scoping review

TLDR
Orexinergic system is involved in the different psychiatric and neurological disorders; therefore, targeting of this system could be possible novel pathway in the management of these disorders.

Orexin and Psychoneurobiology: A Hidden Treasure

TLDR
The orexinergic system is involved in different psychiatric and neurological disorders; therefore targeting of this system could be a possible novel pathway in the management of these disorders.

Hypocretin/Orexin Receptor Pharmacology and Sleep Phases.

TLDR
The broad projections of the hypocretin/orexin-producing neurons, along with differential expression of the two receptors in the projection fields of these neurons, suggest distinct roles for these receptors.

Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis

TLDR
Daridorexant does not impair cardiac repolarization evidenced by absence of relevant QT prolongation at therapeutic and supratherapeutic doses and its pharmacokinetics were consistent with previous data.

Sleep therapeutics and neuropsychiatric illness

  • A. Krystal
  • Psychology, Medicine
    Neuropsychopharmacology
  • 2019
Alterations in sleep are extremely common in patients with neuropsychiatric illness. In addition, sleep disorders such as insomnia, obstructive sleep apnea, rapid eye movement sleep behavior

References

SHOWING 1-10 OF 175 REFERENCES

Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.

  • R. Owen
  • Psychology, Medicine
    Drugs of today
  • 2016
TLDR
Overall tolerability was good, with somnolence being the commonest adverse event and no strong signals for rebound or withdrawal were seen after 1-12 months of treatment and few adverse events suggestive of residual psychomotor or cognitive events have been recorded.

Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.

TLDR
Overall tolerability was good, with somnolence being the commonest adverse event (more than 7% in 3-month studies).

Novel class of medications, orexin receptor antagonists, in the treatment of insomnia – critical appraisal of suvorexant

TLDR
Suvorexant is not likely to replace benzodiazepines or nonbenzodiazepine receptor antagonists as a first-line sleep agent but does represent a novel option for the treatment of patients with chronic insomnia.

Suvorexant: a promising, novel treatment for insomnia

TLDR
More head-to-head studies comparing suvorexant to other sedative-hypnotic therapies are needed to further delineate which patients will benefit the most from this medication over others.

Suvorexant in insomnia: efficacy, safety and place in therapy

TLDR
Suvorexant is the first DORA to be approved and has demonstrated efficacy at decreasing both time to sleep onset and increasing total sleep time compared with placebo, and may represent an alternative for patients who cannot tolerate or do not receive benefit from traditional sleep agents.

Suvorexant for the treatment of insomnia

TLDR
Despite its limitations, suvorexant’s market entry offers a truly novel treatment for insomnia, paving the way for follow-up compounds and opening therapeutic avenues in other disorders for orexin receptor modulating compounds.

Discovery and development of orexin receptor antagonists as therapeutics for insomnia

TLDR
Based on the publication of recent non‐clinical and clinical data, orexin receptor antagonists potentially represent a targeted, effective and well‐tolerated new class of medications for insomnia.

Orexin receptor antagonism for treatment of insomnia

TLDR
The data suggest that orexin receptor antagonism offers a novel approach to treating insomnia, and Class I evidence that suvorexant improves sleep efficiency over 4 weeks in nonelderly adult patients with primary insomnia.

Profile of suvorexant in the management of insomnia

  • E. L. Sutton
  • Medicine, Psychology
    Drug design, development and therapy
  • 2015
TLDR
Suvorexant objectively improves sleep, shortening the time to achieve persistent sleep and reducing wake after sleep onset, although at approved doses (≤20 mg) the benefit was subjectively assessed as modest.
...